Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KROS Keros Therapeutics, Inc.

Trading 04-02 11:29:51 EDT

9.74

+0.19

+1.99%

High9.92	Low9.41	Vol271.16K
Open9.49	D1 Closing9.55	Amplitude5.34%
Mkt Cap395.07M	Tradable Cap345.04M	Total Shares40.56M
T/O2.65M	T/O Rate0.77%	Tradable Shares35.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"KROS","market":"US","secType":"STK","nameCN":"Keros Therapeutics, Inc.","latestPrice":9.74,"timestamp":1743607789708,"preClose":9.55,"halted":0,"volume":271159,"delay":0,"floatShares":35425545,"shares":40562047,"eps":-5.0044,"marketStatus":"Trading","change":0.19,"latestTime":"04-02 11:29:51 EDT","open":9.49,"high":9.92,"low":9.41,"amount":2649405.1065300005,"amplitude":0.053403,"askPrice":9.75,"askSize":310,"bidPrice":9.74,"bidSize":331,"shortable":3,"etf":0,"ttmEps":-5.0044,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743624000000},"marketStatusCode":2,"adr":0,"listingDate":1586318400000,"exchange":"NASDAQ","adjPreClose":9.55,"preHourTrading":{"tag":"盘前","latestPrice":9.49,"preClose":9.55,"latestTime":"09:29 EDT","volume":3576,"amount":34130.853072000005,"timestamp":1743600570019},"postHourTrading":{"tag":"盘后","latestPrice":9.55,"preClose":9.55,"latestTime":"17:08 EDT","volume":7154,"amount":68320.62,"timestamp":1743541688460},"volumeRatio":1.03531,"impliedVol":0.6448,"impliedVolPercentile":0.4582},"requestUrl":"/m/hq/s/KROS","defaultTab":"news","newsList":[{"id":"2524190702","title":"Keros Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524190702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524190702?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:01","pubTimestamp":1743508860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KROS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 08:01 ET (12:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2524949301","title":"Scotiabank Remains a Buy on Keros Therapeutics (KROS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524949301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524949301?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:56","pubTimestamp":1743504969,"startTime":"0","endTime":"0","summary":"In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-buy-on-keros-therapeutics-kros-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-buy-on-keros-therapeutics-kros-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2523971911","title":"Keros Therapeutics reports results from Phase 1 clinical trial of KER-065","url":"https://stock-news.laohu8.com/highlight/detail?id=2523971911","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523971911?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:15","pubTimestamp":1743416152,"startTime":"0","endTime":"0","summary":"Keros Therapeutics (KROS) announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. Topline results from ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-reports-results-from-phase-1-clinical-trial-of-ker-065?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/keros-therapeutics-reports-results-from-phase-1-clinical-trial-of-ker-065?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KROS","LENZ"],"gpt_icon":0},{"id":"2523077916","title":"BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2523077916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523077916?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:04","pubTimestamp":1743415472,"startTime":"0","endTime":"0","summary":"BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy VolunteersMarch 31 (Reuters) - Keros Therapeutics Inc KROS.O:KEROS THERAPEUTICS ANNOUNCES I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC02F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2523915793","title":"Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial of Ker-065 in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2523915793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523915793?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:00","pubTimestamp":1743415213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC02F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2523191575","title":"Keros Therapeutics Inc -Plans on Advancing Ker-065 Into a Phase 2 Clinical Trial in Dmd, Subject to Positive Regulatory Interaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2523191575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523191575?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:00","pubTimestamp":1743415213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC02F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2523157639","title":"Keros Therapeutics Inc: Ker-065 Was Generally Well-Tolerated, With No Major Safety Signals Observed to Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2523157639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523157639?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 18:00","pubTimestamp":1743415213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC02F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2521394702","title":"Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2521394702","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521394702?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:55","pubTimestamp":1742565305,"startTime":"0","endTime":"0","summary":"Shares of Keros Therapeutics, Inc.  have gained 3.7% over the past four weeks to close the last trading session at $11.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $29.40 indicates a potential upside of 157%.However, an impressive consensus price target is not the only factor that indicates a potential upside in KROS. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-think-keros-135505036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2517944772","title":"Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944772","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517944772?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 22:55","pubTimestamp":1741186508,"startTime":"0","endTime":"0","summary":"Keros Therapeutics, Inc.  closed the last trading session at $11.59, gaining 5.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.40 indicates a 153.7% upside potential.The average comprises 10 short-term price targets ranging from a low of $15 to a high of $43, with a standard deviation of $10.46. While the lowest estimate indicates an increase of 29.4% from the current price level, the most optimistic estimate points to a 271% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-believe-keros-145508152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2516300766","title":"Keros Therapeutics CEO to Speak at Major Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2516300766","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516300766?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 06:30","pubTimestamp":1740781835,"startTime":"0","endTime":"0","summary":"The latest update is out from Keros Therapeutics ( ($KROS) ). On February 28, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir See...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-ceo-to-speak-at-major-conferences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-ceo-to-speak-at-major-conferences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","KROS","BK4139"],"gpt_icon":0},{"id":"2516883307","title":"Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2516883307","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516883307?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 06:00","pubTimestamp":1740780000,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., Feb. 28, 2025  -- Keros Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta  family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:. Date and Time: Monday, March 10, 2025 at 1:40 p.m. Eastern time","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-announces-participation-upcoming-220000853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","LENZ","BK4139","KROS","BK4137"],"gpt_icon":0},{"id":"2514390380","title":"Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Kura Oncology (KURA) and Silence Therapeutics (SLN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514390380","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514390380?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 14:40","pubTimestamp":1740724810,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Keros Therapeutics (KROS – Research Report), Kura ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-keros-therapeutics-kros-kura-oncology-kura-and-silence-therapeutics-sln?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-keros-therapeutics-kros-kura-oncology-kura-and-silence-therapeutics-sln?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4505","BK4139","HCSG","KROS","SLN","KURA"],"gpt_icon":0},{"id":"2514333985","title":"Keros Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333985","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514333985?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 01:18","pubTimestamp":1740676680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KROS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 12:18 ET (17:18 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2514806702","title":"Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Oneview Healthcare Chess Depository Interests repr 1 (OtherONVVF) and Teladoc (TDOC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806702?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 20:20","pubTimestamp":1740658811,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Keros Therapeutics (KROS – Research Report), Onevi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-keros-therapeutics-kros-oneview-healthcare-chess-depository-interests-repr-1-otheronvvf-and-teladoc-tdoc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-keros-therapeutics-kros-oneview-healthcare-chess-depository-interests-repr-1-otheronvvf-and-teladoc-tdoc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","LU1861559042.SGD","BK4534","BK4588","BK4567","BK4548","BK4585","KROS","LU1861558580.USD","BK4137","BK4139","TDOC","BK4504","HCSG"],"gpt_icon":0},{"id":"2514890835","title":"TD Cowen Remains a Hold on Keros Therapeutics (KROS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514890835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514890835?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 07:47","pubTimestamp":1740613635,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Keros Therapeutics (KROS – Research Report). The company’s sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-hold-on-keros-therapeutics-kros?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-hold-on-keros-therapeutics-kros?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","COWN","BK4127","BK4566","KROS","TD","BK4207"],"gpt_icon":0},{"id":"2514897264","title":"Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514897264","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514897264?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 06:10","pubTimestamp":1740607806,"startTime":"0","endTime":"0","summary":"Keros Therapeutics, Inc.  came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.58%. A quarter ago, it was expected that this company would post a loss of $1.26 per share when it actually produced a loss of $1.41, delivering a surprise of -11.90%.Keros Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.04 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 97.11%. This compares to year-ago revenues of $0.14 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Keros Therapeutics shares have lost about 31.1% since the beginning of the year versus the S&P 500's gain of 1.3%.While Keros Therapeutics has underperformed the market so far thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-inc-kros-reports-221006728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KROS"],"gpt_icon":0},{"id":"2514958708","title":"Keros Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514958708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514958708?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 05:57","pubTimestamp":1740607053,"startTime":"0","endTime":"0","summary":"Keros Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryKeros Therapeutics Inc KROS.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended De","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL5N3PH2XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS"],"gpt_icon":0},{"id":"2514789823","title":"Keros Therapeutics Q4 EPS $(1.14) Misses $(0.96) Estimate, Sales $3.04M Miss $15.42M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514789823","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514789823?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 05:26","pubTimestamp":1740605214,"startTime":"0","endTime":"0","summary":"Keros Therapeutics Q4 EPS $(1.14) Misses $(0.96) Estimate, Sales $3.04M Miss $15.42M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43990782/keros-therapeutics-q4-eps-1-14-misses-0-96-estimate-sales-3-04m-miss-15-42m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2514867106","title":"BRIEF-Keros Therapeutics Q4 EPS USD -1.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867106?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 05:01","pubTimestamp":1740603705,"startTime":"0","endTime":"0","summary":"BRIEF-Keros Therapeutics Q4 EPS USD -1.14\n\n\nFeb 26 (Reuters) - Keros Therapeutics Q4 net income USD -46.026 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX883E0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS"],"gpt_icon":0},{"id":"2514867160","title":"Keros Therapeutics Q4 EPS USD -1.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867160","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867160?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX883E0B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kerostx.com","stockEarnings":[{"period":"1week","weight":-0.1541},{"period":"1month","weight":-0.1381},{"period":"3month","weight":-0.3967},{"period":"6month","weight":-0.8406},{"period":"1year","weight":-0.8572},{"period":"ytd","weight":-0.3967}],"compareEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0121},{"period":"1year","weight":0.0743},{"period":"ytd","weight":-0.0428}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.013304},{"month":2,"riseRate":0.6,"avgChangeRate":0.081109},{"month":3,"riseRate":0.2,"avgChangeRate":-0.068893},{"month":4,"riseRate":0.2,"avgChangeRate":-0.048421},{"month":5,"riseRate":0.2,"avgChangeRate":-0.110341},{"month":6,"riseRate":0.2,"avgChangeRate":-0.056883},{"month":7,"riseRate":0.6,"avgChangeRate":0.004645},{"month":8,"riseRate":0.4,"avgChangeRate":0.085411},{"month":9,"riseRate":0.6,"avgChangeRate":0.029696},{"month":10,"riseRate":0.6,"avgChangeRate":0.145794},{"month":11,"riseRate":0.6,"avgChangeRate":0.149022},{"month":12,"riseRate":0.4,"avgChangeRate":-0.094035}],"exchange":"NASDAQ","name":"Keros Therapeutics, Inc.","nameEN":"Keros Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Keros Therapeutics, Inc.(KROS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Keros Therapeutics, Inc.,KROS,Keros Therapeutics, Inc.股票,Keros Therapeutics, Inc.股票老虎,Keros Therapeutics, Inc.股票老虎国际,Keros Therapeutics, Inc.行情,Keros Therapeutics, Inc.股票行情,Keros Therapeutics, Inc.股价,Keros Therapeutics, Inc.股市,Keros Therapeutics, Inc.股票价格,Keros Therapeutics, Inc.股票交易,Keros Therapeutics, Inc.股票购买,Keros Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Keros Therapeutics, Inc.(KROS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Keros Therapeutics, Inc.(KROS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}